<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2015-12-22 13:41:24Amphetamine Methylphenidate Attention deficit hyperactivity disorder Euphoriants Stimulants Attention deficit hyperactivity disorder management Lisdexamfetamine Dextroamphetamine Prescription drug Adult attention deficit hyperactivity disorder Pemoline Medical prescription |
Add to Reading List |
prilTreatments for Attention Deficit Hyperactivity Disorder in Adults FINAL PHARMACOEPIDEMIOLOGY REPORT![VYVANSE® [Vī’ - văns] MEDICATION GUIDE (lisdexamfetamine dimesylate) CII Capsules What is the most important information I should know about](https://www.pdfsearch.io/img/2b12fe7a8c2e043e44114574a56ca3dc.jpg "VYVANSE® [Vī’ - văns] MEDICATION GUIDE (lisdexamfetamine dimesylate) CII Capsules What is the most important information I should know about") | VYVANSE® [Vī’ - văns] MEDICATION GUIDE (lisdexamfetamine dimesylate) CII Capsules What is the most important information I should know aboutDocID: 1tcsc - View Document |
| prilTreatments for Attention Deficit Hyperactivity Disorder in Adults FINAL PHARMACOEPIDEMIOLOGY REPORTDocID: 1pBj0 - View Document |
 | prilFINAL CONSOLIDATED REPORT DecemberDrugs Used in the Management ofDocID: 1ou1z - View Document |
 | Microsoft Word - VYVANSE.Product MonographdocDocID: 1m5V8 - View Document |
 | Patient Assistance Program Shire Pharma Canada ULC (“Shire”) developed the VYVANSE Patient Assistance Program (the “Program”) for Canadian patients requiring support by covering for tDocID: 1lpLs - View Document |